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Peroxisome proliferator-activated receptor-γ (PPAR-γ), an essential transcriptional mediator of adipogenesis, lipid metabolism,
insulin sensitivity, and glucose homeostasis, is increasingly recognized as a key player in inﬂammatory cells and in cardiovascu-
lar diseases (CVD) such as hypertension, cardiac hypertrophy, congestive heart failure, and atherosclerosis. PPAR-γ agonists, the
thiazolidinediones (TZDs), increase insulin sensitivity, lower blood glucose, decrease circulating free fatty acids and triglycerides,
lower blood pressure, reduce inﬂammatory markers, and reduce atherosclerosis in insulin-resistant patients and animal models.
Human genetic studies on PPAR-γ have revealed that functional changes in this nuclear receptor are associated with CVD. Recent
controversial clinical studies raise the question of deleterious action of PPAR-γ agonists on the cardiovascular system. These com-
plex interactions of metabolic responsive factors and cardiovascular disease promise to be important areas of focus for the future.
Copyright © 2008 Sheng Zhong Duan et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Cardiovascular disease (CVD) is the major cause of mor-
bidity and mortality in developed countries [1]. Searching
for the underlying risk factors has revealed that a cluster of
contributors is often present simultaneously. This risk factor
clustering, most notably the core trio of insulin resistance,
dyslipidemia, and hypertension, has been called by a number
ofdiﬀerentnamesincludingmetabolicsyndrome(MetS),in-
sulin resistance syndrome, the deadly quartet, and Syndrome
X[ 1–7]. Although somewhat controversial, the usefulness of
clusteringthissyndromeremainsclear.Themechanisticcon-
nections among the trio are not completely understood.
A major focus is to understand the biological and
molecular mechanisms underlying this syndrome and to
develop better treatment. One class of molecules that are
proposed to be important in the etiology of MetS is the
nutrient-sensing nuclear transcription factors, peroxisome
proliferator-activatedreceptors(PPARs),andtherelatedliver
X receptors (LXRs) [7]. Among these nuclear receptors,
PPAR-γ is of intense interest, not only because its ligands,
thiazolidinediones(TZDs),areclinicallyusedforT2DM,but
also because it may be a nexus that connects metabolic dis-
orders to CVD [1, 4–9]. In addition to its important roles
in insulin sensitivity and glucose homeostasis, PPAR-γ is
also associated with CVD such as coronary heart disease,
atherosclerosis, and stroke [7, 10]. MetS is also linked to car-
diachypertrophybecausepopulationswithMetShavehigher
prevalence of cardiac hypertrophy [11–14]. However, action
of PPAR-γ agonists is not only of metabolism in insulin re-
sponsive tissues, but also more directly in the inﬂammatory,
cardiac,andvascularcells.ThecomponentsofMetSarecom-
mon risk factors to CVD [1]. In this review, we will focus on
PPAR-γ in the cardiovascular (CV) system, including its ex-
pression, gain, and loss of function, and the mechanisms by
which it functions in cardiovascular cells.
2. PPAR-γ GENE AND ITS EXPRESSION OF
CV-RELEVANT TISSUES
PPAR-γ is the most extensively studied PPAR, even though
the cloning of this receptor came four years later than that
of PPAR-α [15]. The PPAR-γ gene extends over more than
100 kb of genomic DNA. It includes six common coding ex-
ons: one exon for the N-terminal A/B domain, two exons
for the DNA binding domain, with each one encoding one2 PPAR Research
of the two zinc ﬁngers, one exon for the hinge region, and
two exons for the ligand binding domain in the C-terminal
region [16, 17]. There are two major splice isoforms in the
mouse, PPAR-γ1 and PPAR-γ2, whereas at least two other
isoforms, PPAR-γ3 and PPAR-γ4, have also been identiﬁed
in other species including humans [16]. PPAR-γ1i se n c o d e d
by eight exons, comprising two γ1-speciﬁc exons, A1 and
A2, that constitute the 5 -untranslated region, and the six
coding exons that are common to both γ1a n dγ2m R N A s .
The PPAR-γ1 protein consists of 477 amino acids [16]. The
PPAR-γ2 mRNA is composed of seven exons, the additional
one, exon B, comprising the γ25  -untranslated region and
an additional N-terminal amino acid sequence speciﬁc for
γ2. As a result, PPAR-γ2 is a larger protein, consisting of 505
amino acids [16].
The function PPAR-γ was initially recognized in adi-
pose tissue [18], although its expression was ﬁrst identiﬁed
in other tissues [15]. It is well expressed in cardiovascular-
system-relevant tissues such as heart, endothelium, vascu-
lar smooth muscle, kidney, and macrophages [10, 19–23].
PPAR-γ2 is mainly expressed in adipocytes while PPAR-γ1
is more widely expressed [23].
3. PPAR-γ LIGANDS
Naturalligands
Several polyunsaturated fatty acids and their metabolites
have been identiﬁed as PPAR-γ ligands although no ligand
hasclearlybeenidentiﬁedasacriticalphysiologicligand.En-
dogenous ligands including 15-deoxy-Δ12,14 prostaglandin
J2 (15-d-PGJ2) [24]. 15-d-PGJ2 had been one of the most
promising candidates for the endogenous PPAR-γ ligand. It
bindstoPPAR-γ withadissociationconstant(Kd)inthelow-
micromolar range and can activate PPAR-γ target genes at
concentrations at or near the Kd [25]. However, it has never
beendeﬁnitivelyproventoexistinvivo,norareitseﬀectsthat
are speciﬁc to PPAR-γ [25]. Other natural ligands of PPAR-
γ include 9- and 13-hydroxyoctadecadienoic acid (HODE),
which are components of oxidized low-density lipoprotein
[26], and 12- and 15-hydroxyeicosatetraenoic acid (HETE)
[27]. Some researchers have argued that fatty acids are the
important natural ligands although they are fairly low aﬃn-
ity ligands. A recent class of high-aﬃnity ligands, the ni-
trolipids, has been identiﬁed, but their physiologic function
and the role of PPAR-γ in their eﬀects have not yet been fully
delineated [28].
Syntheticligands
TZDs, or “glitazones,” are a class of pharmaceutical com-
pounds used clinically as insulin sensitizers in patients with
T2DM[17].Theﬁrstclinicallyusedagentinthisclass,trogli-
tazone (Rezulin), was removed from the market because of
rare but life-threatening hepatic toxicity. Fortunately, its suc-
cessors, rosiglitazone (Avandia), and pioglitazone (Actos),
have not been linked to this side eﬀect [23]. More than 15
million prescriptions for these TZDs are dispensed annu-
ally in the United States alone. However, adverse eﬀects such
as edema and weight gain have been problematic [23]. An-
other side eﬀe c to fT Z D si na n i m a l si sc a r d i a ch y p e r t r o -
phy, which has limited the approved doses of these drugs for
clinical use [29–33]. More recently, increased risks of my-
ocardial infarction and possibly death from cardiovascular
causes have been reported to be associated with rosiglitazone
(Avandia)treatment[34],althoughtheresultiscontroversial
[35].
TZDs’“on-target”and“off-target”effects
Compelling evidence has shown that PPAR-γ is the main tar-
get of TZDs. PPAR-γ mediates the insulin sensitizing eﬀects
of TZDs in fat, skeletal muscle, and liver [36–39]. TZDs’ ef-
fects on ﬂuid retention and weight gain are also dependent
on PPAR-γ [40, 41]. However, several studies demonstrate
that some of TZDs’ eﬀects are independent of PPAR-γ or
“oﬀ-target.” In macrophages, it has been recognized that al-
though TZDs modulate lipid metabolism through PPAR-γ,
some of TZDs’ anti-inﬂammatory eﬀects are independent of
it [42] although only at higher doses. Some of the antiprolif-
erative eﬀects of TZDs in embryonic stem cells [43]o rc a n -
cer cell lines [44, 45] are independent of PPAR-γ. Further,
PPAR-γ in skeletal muscle and liver may not be mediating
TZDs’ insulin sensitizing eﬀects under diﬀerent conditions
or in diﬀerent models [38, 39, 46]. Loss-of-function studies
have provided additional insight on the possible “oﬀ-target”
eﬀects of TZDs.
Understanding which TZD eﬀects are PPAR-γ indepen-
dent is an important issue for designing more speciﬁc PPAR-
γ agonists with fewer side eﬀects. TZDs induce cardiac hy-
pertrophy in animals [29–33] independent of cardiac PPAR-
γ [47]. TZDs also increase the incidence of congestive heart
failure [48] presumably due to ﬂuid retention caused by
PPAR-γ activation in the kidney [40, 41]. Myocardial infarc-
tion incidence is increased in meta-analysis of clinical trials
[34], but it is not known whether this side eﬀect is medi-
ated by PPAR-γ or whether this ﬁnding will be conﬁrmed in
aprospectivestudy[35].Further,deﬁningtheroleofPPAR-γ
in these eﬀects would provide guidance for the design of the
next generation of TZDs.
4 . G A I NA N DL O S SO FP P A R - γ FUNCTION
IN THE CV SYSTEM
Although originally found to be critical in adipogenesis and
regulating insulin signaling, PPAR-γ is also important in
CV system [16, 17, 49, 50]. Human genetic studies have re-
vealed that PPAR-γ mutation in humans can result in either
gain-of-function or loss-of-function [51]. In animals, gain-
of-function studies of PPAR-γ have mostly utilized agonists,
particularly synthetic ones (TZDs); Loss-of-function stud-
ies have used knockdown or knockout and transgenic mouse
models of mutant PPAR-γ, which are powerful tools to study
physiological mechanisms. The outcome of these approaches
instudyingPPAR-γ inCVsystemhasbeenfruitfulandsome-
times surprising.Sheng Zhong Duan et al. 3
Humanmutations
Pro12Ala mutation is a loss-of-function mutation and has
been reported to be associated with not only increased pro-
tection against insulin resistance and type-2 diabetes [52–
56], but also a decreased incidence of myocardial infraction
[57] and lower diastolic blood pressure [58]. These cardio-
vascular eﬀects are likely independent of metabolic impact
of this mutation [57, 58].
Pro467Leu, Val290Met, Phe388Leu, and Arg425Cys are
all loss-of-function mutations (dominant negative) and have
beenassociatedwithpartiallipodystrophy,insulinresistance,
diabetes,andhypertension[59–62],althoughitisnotknown
whether the elevated blood pressure is due to impaired in-
sulin sensitivity.
C161T mutation is a silent polymorphism and has been
reported to be associated with reduction in coronary artery
disease, likely independent of obesity and of lipid abnormal-
ities, possibly through direct eﬀects on local vascular wall,
implicating the protective role of PPAR-γ in atherogenesis
[63].
However, ligand binding domain mutants of PPAR-γ
with dominant negative actions have been shown to be
promiscuous, stimulate associations with nuclear receptor
corepressor (N-CoR) and silencing mediator of retinoid and
thyroid receptors (SMRT), and inhibit activities of all three
wild-type PPARs [64]. These less speciﬁc properties of the
mutants need to be explored in the human mutations to de-
termine which eﬀects on metabolic syndrome are mediated
through PPAR-γ or the PPARs, PPAR-α or PPAR-δ.
Germlinegeneinactivation
HomozygousgermlinePPAR-γ knockoutmicedieatE10due
to defects in trophoblast [65, 66]. Heterozygous mutations
are viable, have less adipose tissue, and are more insulin sen-
sitive than wild-type counterparts [67, 68]. This illustrates
the complex response to gene dosage of PPAR-γ.
PPAR-γ andhypertension
PPAR-γ agonistscanlowerbloodpressureandthiseﬀectmay
be at least partially independent of their insulin-sensitizing
eﬀects [17, 49, 50]. Dominant negative mutation of PPAR-γ
(Pro467Leu) in mice results in hypertension and fat redistri-
bution but not insulin resistance or diabetes seen in the same
mutation in humans [69]. Another line of dominant neg-
ative PPAR-γ mutant mice (Leu466Ala) have hypertension
(femaleonly)andinsulinresistance[70].Asdiscussedabove,
dominant negative PPAR-γ mutants can be more promiscu-
ous, inhibiting activity of other PPARs, so we cannot at this
pointconcludethatthesemutantsstrictlyactbyalteringonly
PPAR-γ activity [64]. Therefore, comparison to loss of func-
tion mutants and knockouts is critical.
Embryonic lethality of the germline PPAR-γ knockout
has been rescued by breeding Mox2-Cre, in which Cre re-
combinase is expressed in epiblast-derived tissue but not
other tissues, to ﬂoxed PPAR-γ mice [71]. The generalized
PPAR-γ knockout mice have lipodystrophy and insulin resis-
tance as expected. Surprisingly, they have hypotension rather
than hypertension. This is paradoxical because PPAR-γ ag-
onists lower blood pressure [72–74]. Knockout and agonist
having the same phenotype may be resolved by testing the
hypothesis that PPAR-γ suppresses certain key gene expres-
sion to control blood pressure and that both agonist and
knockout can relieve the suppression. Further, the pheno-
types in the generalized PPAR-γ knockout mice suggest that
hypertension is separable from lipodystrophy or insulin re-
sistance, even though they are highly associated in humans
[59, 61] and in A-ZIP mice [71]. Mechanistically, the vascu-
lature from these generalized PPAR-γ knockout mice has de-
fects in both relaxation and contraction, contributing to the
hypotension.
It has not been completely determined whether the hy-
potension phenotype seen in the generalized PPAR-γ knock-
out mice is attributable to PPAR-γ deﬁciency in vascular en-
dothelium or smooth muscle or both. Endothelium-speciﬁc
PPAR-γ knockout mice are reported to be not having any
phenotype at baseline, although this study only used tail cuﬀ
to measure the blood pressure [75]. When fed with high fat
diet, they have higher blood pressure and heart rate than
theirwildtypecontrolmice.Rosiglitazonedoesnotaﬀectthe
diet-induced hypertension in these knockout mice, although
the decrease of blood pressure typically seen in treated wild-
type control mice was not reported [75]. Smooth muscle-
speciﬁc PPAR-γ knockout mouse model may clarify the
role of smooth muscle PPAR-γ in blood pressure regula-
tion.
The kidney is an important organ in controlling blood
pressure and PPAR-γ is expressed in this organ, although
PPAR-γ deﬁciency in collecting duct does not alter blood
pressure in mice [40, 41]. The knockout does block weight
gain, ﬂuid retention, and blood volume expansion caused by
TZDs [40, 41]. These results indicate that PPAR-γ deﬁciency
incollectingductisunlikelytocontributetothehypotension
phenotype seen in the generalized PPAR-γ knockout mice
[71].
PPAR-γ andcardiachypertrophy
PPAR-γ agonists have been shown to inhibit hypertrophy of
cultured neonatal rat ventricular cardiomyocytes induced by
mechanical stress or angiotensin II, and cardiac hypertro-
phy induced by aortic constriction in rats and mice [76–78].
The inhibition on hypertrophy was accompanied by the in-
hibition on expression of embryonic genes, including atrial
natriuretic peptide (ANP), brain natriuretic peptide (BNP),
skeletal α-Actin, as well as that of endothelin-1 that can in-
ducecardiachypertrophy[76–78].Aorticconstrictioncauses
more profound cardiac hypertrophy in heterozygous PPAR-
γ knockout mice than wild-type controls, further indicat-
ing the involvement of PPAR-γ in cardiac growth [77]. Nu-
c l e a rF a c t o r - K a p p aB e t a( N F - κB) pathway is at least partially
mediating the inhibition on hypertrophic growth in vitro
[76]. More recently, pioglitazone has been reported to in-
hibit the gene expression of inﬂammatory cytokines such
as interleukin (IL)-1β,I L - 6[ 79], suggesting the possible in-
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hypertrophy. Paradoxically, TZDs also induce cardiac hyper-
trophy in mice, rats, and dogs [30–33].
The cardiomyocyte-speciﬁc PPAR-γ knockout mice have
age-progressive cardiac hypertrophy with preserved systolic
cardiacfunction[47].Rosiglitazoneinducecardiachypertro-
phy in both knockout mice and wild-type littermate control
mice, demonstrating that this TZD’s hypertrophic eﬀect is
at least partially independent of PPAR-γ in cardiomyocytes
[47]. Whether the cardiac hypertrophy caused by rosigli-
tazone occurs through PPAR-γ independent eﬀects in car-
diomyocytes, PPAR-γ in nonmyocyte cells, or blood vol-
ume expansion [33, 48], remains to be further determined.
Studying these knockout mice under pathological stimula-
tions such as pressure overload may yield more meaning-
ful results to understand the function of PPAR-γ in the
heart.
Rosiglitazone and cardiomyocyte-speciﬁc PPAR-γ
knockout activate distinctly diﬀerent hypertrophic pathways
[47]. Rosiglitazone increases phosphorylation of both p38
mitogen-activated protein kinase (p38-MAPK) and extra-
cellular signal-related kinase (ERK) 1/2 in the heart. The
activation of p38-MAPK is independent of cardiomyocyte
PPAR-γ and that of ERK1/2 is dependent. The activation
o fe i t h e rE R K so rp 3 8 - M A P Ki ss u ﬃcient to induce hyper-
trophy [80, 81] and may therefore contribute to the cardiac
hypertrophy induced by rosiglitazone.
The cardiomyocyte-speciﬁc PPAR-γ knockout mouse
hearts were found to have increased expression of cardiac
embryonic genes ANP and β-myosin heavy chain (β-MHC),
and elevated NF-κB activity. Embryonic gene expression in
adult hearts is a one of the characteristics of pathological
cardiac hypertrophy [82, 83]. NF-κB is both necessary and
suﬃcient for hypertrophic growth of cardiomyocytes [84].
Therefore, NF-κB activation is likely to be part of the mech-
anisms that PPAR-γ deﬁciency in cardiomyocytes induces
cardiac hypertrophy. However, the interaction between these
two transcription factors needs to be further characterized.
Another cardiomyocyte-speciﬁc PPAR-γ knockout
mouse line also has progressive cardiac hypertrophy and
accompanied elevation of cardiac gene expression (ANP and
skeletal α-actin) [85]. However, these mice also have dilated
cardiomyopathy, heart failure, and mitochondrial oxidative
damage. Increased myocardial superoxide content, instead of
NF-κB activation, seems to be mediating the severe cardiac
phenotype [85]. Similarly, when diﬀerent ﬂoxed PPAR-γ
mice were used to delete this receptor in skeletal muscle
speciﬁcally,onemouseline[37] had more severe phenotypes
than the other [46]. It is not clear whether these phenotypic
diﬀerences are because of the diﬀerent genetic design for the
deletion or purely genetic background diﬀerences.
PPAR-γ,inﬂammation,andatherosclerosis
PPAR-γ is not only expressed in macrophages, endothelial
cells,and smooth muscle cellsin normal vasculature[10, 19–
23], but also in atherosclerotic lesions [86, 87]. PPAR-γ ag-
onists reduce atherosclerosis in human patients and animal
models [88–92] even though there were concerns that these
compounds could be proatherogenic because they may pro-
mote the macrophages uptake of lipids and speed the foam
cell formation [26]. These antiatherogenic eﬀects can be in-
dependent of their beneﬁcial eﬀects on metabolism [93, 94].
MoredirectantiatherogenicfunctionofPPAR-γ wasdemon-
strated by the result that transplantation of PPAR-γ deﬁcient
bone marrow to low-density lipoprotein (LDL) receptor null
mice led to a signiﬁcant increase in atherosclerosis [95]. The
beneﬁcial eﬀects are largely attributable to PPAR-γ’s anti-
inﬂammation activity and its role in modulating lipid home-
ostasis in macrophages.
Vascular inﬂammation has been increasingly appreciated
as an important factor in the pathogenesis of atherosclero-
sis [96–99] .T h ei m p o r t a n c eo fm a c r o p h a g eP P A R - γ in CVD
has begun to be appreciated since foam cells in atheroscle-
rotic lesions were found to have high level of PPAR-γ ex-
pression [86, 87]. PPAR-γ activation decreases inﬂamma-
tory cytokines (e.g., tumor necrosis factor-α, IL-6, and IL-
1β) produced by macrophages [100, 101]. By inducing the
expression of LXR-α and ATP-binding cassette A1, PPAR-
γ activation promotes cholesterol eﬄux from macrophages
resulting in inhibition of foam cell formation [95]. Con-
sistently, macrophage-speciﬁc PPAR-γ knockout mice have
reduced basal cholesterol eﬄux, most likely because of de-
creased expression of lipoprotein lipase, scavenger receptor
CD36, LXR-α, and ATP-binding cassette G1 [21]. More pro-
found eﬀects on macrophages by PPAR-γ are also possible
since it has been recently shown that PPAR-γ controls alter-
native activation of macrophages and can thereby improve
insulin resistance [102]. It is likely that this eﬀect on dif-
ferentiation of macrophages is also important in eﬀects of
CVD.
Endothelial cells play a key role in the inﬂammatory pro-
cess of vasculature responding to injuries [96–99]. TZDs
have been shown to reduce superoxide generation and in-
hibit the expression of vascular cell adhesion molecule-1, in-
tercellular cell adhesion molecule-1, and lectinlike oxidized
LDL receptor, and hence inhibit inﬂammation in endothelial
cells [103–106], suggesting an important role of endothelial
PPAR-γ in the development of atherosclerosis. The existing
endothelium-speciﬁc PPAR-γ knockout mice [75] and gen-
eralized PPAR-γ knockout mice [71] can be useful tools to
study the function of endothelial PPAR-γ in atherosclerosis.
Diﬀerent cell types are reported to have diﬀerent mech-
anisms for PPAR-γ to inhibit inﬂammation. In intesti-
nal Caco-2 cells, PPAR-γ inhibits inﬂammation by bind-
ing to NF-κB and facilitating its nuclear export [107]. In
macrophages, PPAR-γ prevents corepressor complex N-CoR
dissociationfromthepromotersofNF-κBresponsiveinﬂam-
matory gene inducible nitric oxide synthase and therefore
represses its expression [108]. It remains to be determined
whether PPAR-γ in endothelial or other vascular cells uses
one of these pathways or an entirely diﬀerent mechanism.
The growth and movement of vascular smooth mus-
cle cell within neointima is one of the key steps leading to
the formation of atherosclerotic plaque [96]. PPAR-γ ago-
nists have been shown to block the proliferation and increase
the apoptosis of vascular smooth muscle cells, suggesting
more beneﬁcial eﬀects of PPAR-γ activation in vasculature
[109, 110].Sheng Zhong Duan et al. 5
Table 1: Cardiovascular phenotypes in gain and loss of PPAR-γ function.
CH MI BP CAD AS
TZDs Agonism Gain of function ↑
∗ [30–33, 47] ↑
∗∗ [34] ↓ [17, 49, 50] ↓ [87–91]
Pro12Ala Human mutation Loss of function ↓ [57] ↓ [58]
Pro467Leu Human mutation Loss of function ↑ [59, 60]
Val290Met Human mutation Loss of function ↑ [60]
Phe388Leu Human mutation Loss of function ↑ [61]
Arg425Cys Human mutation Loss of function ↑ [62]
C161T Human mutation Loss of function ↓ [63]
Pro467Leu Mouse mutation Loss of function ↑ [69]
Leu466Ala Mouse mutation Loss of function ↑ [70]
Generalized KO Transgenic mouse Loss of function ↑ [71] ↓ [71]
Cardiac KO Transgenic mouse Loss of function ↑ [47]
Endothelial KO Transgenic mouse Loss of function → [75]
Collecting duct KO Transgenic mouse Loss of function → [40, 41]
TZDs: thiazolidinediones; KO: knockout; CH: cardiac hypertrophy;
MI: myocardial infarction; BP: blood pressure; CAD: coronary artery disease; AS: atherosclerosis
∗: in animals only; ∗∗: rosiglitazone only
Numbers in square brackets are the reference numbers.
PPAR-γ andcardiacremodeling
Cardiac remodeling after ischemic injury is one of the major
causes that lead to heart failure [111, 112]. The remodeling
process is characterized by myocyte hypertrophy and cardiac
ﬁbrosis [111, 112]. PPAR-γ agonists attenuate this remodel-
ingprocessafterischemiainexperimentalanimals[113].Re-
cent in vitro studies on PPAR-γ in cardiac ﬁbroblasts, a ma-
jorsourceofﬁbrillarcollagensthatleadtoﬁbrosis[111,112],
have revealed more mechanistic insights.
Pioglitazone reduces cell growth, synthesis of collagen
type I, and expression of matrix metalloproteinase-1 in car-
diac ﬁbroblasts undergone anoxia-reoxygenation or treated
with angiotensin II, likely through inhibition of reactive oxy-
gen species generation and NF-κBa c t i v a t i o n[ 114, 115].
Brain natriuretic peptide has been implicated in these eﬀects
[116]. In cultured cardiac ﬁbroblasts, PPAR-γ agonists in-
duce the expression of vascular endothelial growth factor, a
crucial player in the infarcted/ischemic heart, further indi-
cating the beneﬁcial eﬀects of PPAR-γ agonists in cardiac re-
modeling [117]. However, all of these studies are based upon
gain-of-function results. Further investigation using loss-of-
function studies would advance our understanding the role
of PPAR-γ in cardiac ﬁbroblasts and cardiac remodeling and
provide more therapeutic guidance.
PPAR-γ incardiovascularsideeffectsofTZDs
Despite the obviously beneﬁcial eﬀects that TZDs have in
CV system [118], these compounds have some cardiovascu-
lar side eﬀects that are dangerous to be overlooked. As men-
tioned above, TZDs induce cardiac hypertrophy in animals,
a limitation to the dosages in their clinic use.
Congestive heart failure remains to be one of the major
contraindications to the clinical use of TZDs [48]. This is
presumed to be secondary to the ﬂuid retention caused by
activation of PPAR-γ in the kidney, likely in the collecting
duct [40, 41]. Collecting duct knockouts of PPAR-γ is able
to excrete salt loads more easily although there is no end ef-
fect on blood pressure on normal salt diets [40, 41]. PPAR-γ
knockout blocked the eﬀect of TZD on mRNA expression of
the sodium channel ENaC-γ although the baseline level in
the knockout was higher [40].
One recent report regarding the association between
rosiglitazone treatment and signiﬁcantly increased risk in
myocardial infarction as well as an increased risk with bor-
derline signiﬁcance in death from cardiovascular causes has
brought a lot of attention to the safety of this drug [34]. The
ﬁndings were based on limited access to the original data,
and meta-analysis used to reach the conclusions is always
considered less convincing than a large prospective trial de-
signed to assess the outcome of interest. Such a prospective
study is indeed ongoing and the investigators performed an
interim analysis and found that rosiglitazone was not signiﬁ-
cantly associated with increased risk of myocardial infarction
and death from cardiovascular causes, although the ﬁndings
were inconclusive because of the incompleteness of the study
[35]. One side eﬀect of rosiglitazone this interim analysis did
conﬁrm is the increased incidence of heart failure [35].
Although the ﬁndings need to be conﬁrmed, the possi-
ble adverse eﬀects of rosiglitazone in myocardial infarction
and death from cardiovascular causes are worrisome due to
the fact that diabetic patients are already at higher risk for
cardiovascular diseases. The mechanisms of the possible ad-
verse eﬀects are uncertain, and could involve myocardial as
well as vascular changes. Pioglitazone, another member in
the same TZD class, does not seem to have these side eﬀects
[119]. In comparison to rosiglitazone, pioglitazone appears
to have more beneﬁcial eﬀects on lipid proﬁle [120], which
may be one of the contributors to these side eﬀects.However,
the exact mechanisms and molecular basis are yet to be ex-
plored. In order to ultimately understand this drug and help6 PPAR Research
new drug design, it is critical to address questions such as
whether PPAR-γ is mediating these eﬀects of rosiglitazone
and whether heart (cardiomyocytes, cardiac ﬁbroblasts, en-
dothelial cells, or smooth muscle cells) is the direct target.
The cardiovascular phenotypes of these gain- or loss-of
function studies are summarized in Table 1.
5. CONCLUSIONS
PPAR-γ is now ﬁrmly established as an important player in
cardiovascular diseases. Understanding the mechanisms of
PPAR-γ action in heart and vascular cells where action on
NF-κB appears to be important in controlling growth and
inﬂammation may lead to improved targeting of the PPAR-γ
activity in these cells. The interactions of PPAR-γ with other
nuclear transcription factors which have partially overlap-
ping eﬀects such as the PPAR-α,P P A R - δ, and LXR will likely
reveal a complex control system of inﬂammatory and growth
responses to nutrient signaling.
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